Investment Thesis
Despite strong balance sheet fundamentals and 78% gross margins, Edwards Lifesciences exhibits critical warning signs: negative free cash flow of -21.1M, EPS declining 73.7% YoY despite massive revenue growth, and operating cash flow of only 43.8M against 380.7M net income indicating severe cash conversion issues. The 29843% revenue growth suggests non-organic expansion (acquisition) that is not translating to shareholder value, evidenced by deteriorating ROE (3.7%) and ROA (2.9%).
Strengths
- Exceptional balance sheet with 0.06x debt/equity ratio and 2.4B cash position
- Strong profitability margins: 78% gross margin, 29% operating margin, 23.1% net margin
- Excellent liquidity with 4.42x current ratio and 27.1x interest coverage ratio
Risks
- Negative free cash flow of -21.1M despite positive net income indicates poor earnings quality and working capital deterioration
- Diluted EPS collapsed 73.7% YoY despite 29843% revenue growth, signaling severe share dilution or non-accretive M&A activity
- Abysmal capital efficiency: ROE of 3.7% and ROA of 2.9% indicate deployed capital is generating minimal returns
Key Metrics to Watch
- Free cash flow conversion and operating cash flow sustainability
- Organic revenue growth rate excluding acquisition impact
- Earnings per share trajectory and share dilution patterns
Financial Metrics
Revenue
1.6B
Net Income
380.7M
EPS (Diluted)
$0.66
Free Cash Flow
-21.1M
Total Assets
13.3B
Cash
2.4B
Profitability Ratios
Gross Margin
78.0%
Operating Margin
29.0%
Net Margin
23.1%
ROE
3.7%
ROA
2.9%
FCF Margin
-1.3%
Balance Sheet & Liquidity
Current Ratio
4.42x
Quick Ratio
3.63x
Debt/Equity
0.06x
Debt/Assets
22.5%
Interest Coverage
27.14x
Long-term Debt
598.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T06:19:34.299157 |
Data as of: 2026-03-31 |
Powered by Claude AI